<DOC>
	<DOC>NCT02487732</DOC>
	<brief_summary>To investigate pleiotropic effects of ticagrelor in addition to its antiplatelet effects in type 2 diabetic patients with non-ST elevation acute coronary syndrome by measuring inflammatory markers, circulating number of endothelial progenitor cells, brachial artery endothelial function, and arterial stiffness.</brief_summary>
	<brief_title>Comparison of Ticagrelor vs. Prasugrel on Inflammation, Arterial Stiffness, Endothelial Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST Elevation Acute Coronary Syndrome (NSTE-ACS) Requiring Coronary Stenting</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>1. Provision of informed consent prior to any study specific procedures 2. Newly diagnosed type 2 diabetic patients or type 2 diabetic patients on hypoglycemic agents between the age of 30 to 70 3. NonST elevation Acute coronary syndrome with successful coronary stent implantation (with TIMI flow grade 3 after the procedure) 1. Hypersensitivity to ticagrelor, prasugrel or any of the excipients 2. No prior use of either ticagrelor or prasugrel within a month prior to randomization. 3. History of intracranial bleeding at any time 4. Active pathologic bleeding 5. Hemoglobin A1c &gt;9% 6. Type 1 diabetes 7. Decreased serum platelet level (&lt; 100,000/uL) 8. Need for chronic oral anticoagulant therapy or chronic lowmolecularweight heparin 9. Gastrointestinal bleed within the past 6 months, or major surgery within 30 days 10. Renal failure requiring dialysis or anticipated need for dialysis during the course of the study 11. Any condition which in the opinion of the investigator would make it unsafe or unsuitable for the patient to participate in this study 12. Involvement in the planning and/or conduct of the study 13. Left ventricular ejection fraction &lt; 40% 14. Hepatic dysfunction (aspartate aminotransferase or alanine aminotransferase &gt; twice the upper limit) 15. Gastrointestinal disorder such as Crohn`s disease 16. Alcohol abuse 17. Steroid or hormone replacement therapy 18. Serum creatinine &gt; 2.0 mg/dL. 19. Prior history of CVA or stroke 20. Body weight &lt; 60 kg 21. Life expectancy less than a year 22. Known pregnancy, breastfeeding, or intend to become pregnant during the study period</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Diabetic Patients With Non-ST Elevation</keyword>
</DOC>